Abstract
The aim of this study was to compare the predictive value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and other frequently used biomarkers, such as creatine kinase (CK), creatine kinase-mB (CK-MB), cardiac troponin T (cTnT) and C-reactive protein (CRP) for systolic and diastolic left ventricular function (SLVF and DLVF), and adverse coronary events in patients with non-ST-segment elevation acute coronary syndrome. The research was carried out within a group of 75 patients. Patients with referent NT-proBNP levels (<14.75 pmol/l) had significantly less compromised SLVF as compared to patients with elevated NT-proBNP levels.Initially determined levels of NT-proBNP showed statistically significant correlations with all parameters of left ventricular function measured on the control examination, while other biomarkers, except creatine kinase, did not. High sensitivity and negative predictive value of NT-proBNP for SLVF (up to 95.1 and 88.9%, respectively) and adverse coronary events (up to 100.0%) was found. These results make us assume that NT-proBNP may be the single best predictor of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes. Key words: Cardiovascular disease, serum biomarkers, left ventricular function, myocardial infarction, unstable angina.
Highlights
Acute coronary syndromes are a major cause of morbidity and mortality (Goodman et al, 2009)
Determined levels of NT-proBNP showed statistically significant correlations with all parameters of left ventricular function measured on the control examination, while other biomarkers, except creatine kinase, did not
High sensitivity and negative predictive value of NT-proBNP for Systolic left ventricular function (SLVF) and adverse coronary events was found. These results make us assume that NT-proBNP may be the single best predictor of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes
Summary
Acute coronary syndromes are a major cause of morbidity and mortality (Goodman et al, 2009). The term “acute coronary syndrome” (ACS) refers to a range of thrombotic coronary artery diseases, including unstable angina (UA) and both ST-segment elevation (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) (Achar et al, 2005; Thygesen and Alpert, 2001). Advances in our understanding of the pathophysiology of ACS have led to the marked increase in development of biomarkers for diagnosis, risk stratification, therapeutic decision-making and assessment of clinical outcomes (Anderson et al, 2007; Bonaca and Morrow, 2008; Moe and Wong, 2010). There are several biomarkers that are widely used for the previously mentioned purposes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
